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ABSTRACT
Uterine artery (UtA) adenovirus (Ad) vector-mediated overex-
pression of vascular endothelial growth factor (VEGF) enhances
uterine blood flow in normal sheep pregnancy and increases fetal
growth in the overnourished adolescent sheep model of fetal
growth restriction (FGR). Herein, we examined its impact on
gestation length, neonatal survival, early postnatal growth and
metabolism. Singleton-bearing ewes were evenly allocated to
receive Ad.VEGF-A
165
(5 3 1010 particles/ml, 10 ml, n ¼ 17) or
saline (10 ml, n¼ 16) injected into each UtA at laparotomy (0.6
gestation). Fetal growth was serially monitored (blind) by
ultrasound until delivery. Lambs were weighed and blood was
sampled weekly and a glucose tolerance test performed (68-day
postnatal age). Hepatic DNA/RNA was extracted at necropsy (83-
day postnatal age) to examine methylation status of eight
somatotropic axis genes. IGF1 mRNA and protein expression
were measured by RT-PCR and radioimmunoassay, respectively.
All pregnancies remained viable following Ad.VEGF-A
165
treat-
ment. Fetal abdominal circumference and renal volume were
greater in the Ad.VEGF-A
165
group compared with the saline
group at 21/28 days (P  0.04) postinjection. At delivery,
gestation length (P¼0.07), lamb birthweight (P¼0.08), umbilical
girth (P ¼ 0.06), and plasma glucose (P ¼ 0.09) tended to be
greater in Ad.VEGF-A
165
-treated lambs. Levels of neonatal
intervention required to ensure survival was equivalent between
groups. Absolute postnatal growth rate (P ¼ 0.02), insulin area
under the curve (P ¼ 0.04) and carcass weight at necropsy (P ¼
0.04) were increased by Ad.VEGF-A
165
treatment. There was no
impact on markers of insulin sensitivity or methylation/expression
of key genes involved in somatic growth. Ad.VEGF-A
165
gene
therapy increased fetal growth in a sheep FGR model, and lambs
continued to thrive during the neonatal and early postnatal
period.
gene therapy, intrauterine growth restriction (IUGR), metabolism,
sheep, vascular endothelial growth factor
INTRODUCTION
Fetal growth restriction (FGR), a condition in which the fetus
fails to achieve its genetically predetermined growth potential,
remains a leading cause of stillbirth and neonatal death [1].
Survivors of FGR are susceptible to a wide range of
neonatal complications [2] and, thereafter, are at increased risk
of cardiovascular and metabolic disease in later life [3],
including insulin resistance and type II diabetes mellitus.
FGR is commonly caused by uteroplacental insufficiency,
which is characterized by reduced uterine blood flow (UBF). UBF
represents a potential target therapeutically. Our research group
has previously demonstrated that localized adenovirus (Ad)-
mediated overexpression of vascular endothelial growth factor
(VEGF) in the uterine arteries (UtAs) of midgestation pregnant
sheep produces a sustained increase in UBF, which appears to be
mediated by increased endothelial nitric oxidase synthase
expression short term, and perivascular adventitial angiogenesis
long term [4, 5]. Moreover, we recently showed that maternal
UtA Ad.VEGF-A
165
gene therapy significantly increased ultra-
sonographic fetal growth and reduced the proportion of fetuses
with marked FGR in an ovine paradigm of FGR induced by
overnourishment of adolescent ewes [6]. Our previous study was
electively terminated in late pregnancy to allow for detailed
analysis of fetal outcomes. In this new study, using similar
methods, we explored the potential impact of maternal UtA
Ad.VEGF-A
165
gene therapy on gestation length, perinatal
survival, and wellbeing.
The overnourished adolescent sheep paradigm of FGR
replicates the main features of human FGR, including a major
reduction in UBF as a key underlying defect [7–9]. Over-
nourishment adversely impacts nutrient partitioning in the
adolescent mother and promotes her own growth at the expense
of the conceptus. This results in uteroplacental growth restriction
of varying degrees, leading to impaired fetal nutrient supply.
Approximately 50% of lambs born to overnourished mothers are
defined as markedly FGR, in which birth weight is more than
two standard deviations below the mean birth weight of
normally grown fetuses of contemporaneous control-intake
ewes [10, 11]. This model also replicates the prematurity and
increased perinatal mortality rates associated with human FGR.
Typically, spontaneous delivery occurs 3–5 days early in
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individual studies, the amount of colostrum harvested immedi-
ately after birth is hugely attenuated, and, in severe cases,
lactation and the formation of an adequate ewe-lamb bond is
delayed [12–14]. In the absence of human intervention, this has
profound consequences for the smallest and most premature
lambs [15], which can largely be prevented by a proactive
regimen of intensive neonatal care. Once released from the
nutritionally constrained prenatal environment, FGR lambs
exhibit rapid catch-up growth (increased fractional growth rates)
with evidence of increased adiposity and reduced bone mineral
density (BMD) at 11 wk of age (weaning) when assessed by
dual-energy X-ray absorptiometry (DEXA) [15]. At 7 wk of age,
fasting plasma glucose and insulin levels are increased, which
represents a reversal of the pattern observed in late pregnancy, at
which stage growth-restricted fetuses are hypoglycemic and
hypoinsulinemic relative to normally growing fetuses [16–19].
Glucose-stimulated insulin secretion (given by the area under the
curve [AUC] of plasma insulin over time following a
standardized i.v. glucose bolus), fasting insulin-to-glucose and
insulin AUC-to-glucose AUC ratios are also increased, which is
indicative of relative insulin resistance [11].
The impact of FGR on postnatal growth and metabolism
represents an intrauterine programming effect, which may at
least partially involve epigenetic alterations of genes, leading to
changes in gene expression in the absence of any modification of
the DNA base sequence [20]. The most extensively studied
epigenetic marker to date is DNA methylation, which occurs
selectively at sites where a cytosine (C) base precedes a guanine
(G), termed CpG dinucleotides. CpGs cluster in regions called
CpG islands, which are frequently located within or close to the
promoter regions of genes. Relative hypomethylation is
associated with increased gene expression, while hypermethy-
lation leads to reduced expression or even gene silencing.
Several rodent models of FGR are characterized by changes in
DNA methylation [21–23] in various genes, including insulin-
like growth factor 1 (IGF1), which is the principal determinant
of early postnatal growth [24]; however, there is a paucity of
data in ovine paradigms of FGR. Arguably, the sheep is a more
clinically relevant model for human pregnancy, given the
potential to study singleton gestation, comparable maternal size
and adiposity, maternal-to-fetal weight ratio, gestation length,
birth weight, similar organogenesis for all major body systems,
equivalent rates of prenatal protein accretion and fat deposition,
and relative maturity at birth.
We hypothesized that prenatal maternal Ad.VEGF-A
165
gene therapy, through effects on fetal growth, would influence
gestation length, increase birth weight, and mitigate the
negative impact of FGR on neonatal growth and metabolism.
Our aims were to: 1) determine the effects of midgestation
Ad.VEGF-A
165
UtA injection in FGR sheep pregnancies on
gestation length and lamb birth weight; 2) assess safety by
comparing the level of neonatal care required to ensure lamb
survival between treated and untreated groups; 3) examine
whether prenatal maternal Ad.VEGF-A
165
treatment is able to
mitigate the metabolic phenotype previously observed in early
postnatal life; and 4) evaluate the potential impact on the
somatotropic axis by measuring DNA methylation of key
genes with relevance to postnatal growth and metabolism.
MATERIALS AND METHODS
Experimental Animals
Animal procedures were approved by the UK Home Office, under the
Animals (Scientific Procedures) Act 1986 and by local ethics committee
review. Ewes were housed in individual pens under natural lighting conditions
at the Rowett Institute of Nutrition and Health (578N, 28W). Embryos (high-
quality early morulae) were derived from seven superovulated adult donor ewes
(Scottish Blackface3 Border Leicester) 4 days after insemination by a single
sire (Dorset Horn) and synchronously transferred into the uteri of 44 adolescent
recipient ewes (Dorset Horn3Mule) of similar age, weight (43.4 6 1.99 kg),
and adiposity (body condition score, 2.3 6 0.08) in order to establish
exclusively singleton pregnancies of precisely known gestational age and
maximum genetic homogeneity, as described previously [25]. Following
embryo transfer and throughout gestation, adolescent recipients were offered a
complete diet ad libitum in order to restrict placental and fetal growth [26]. The
diet provided 12 MJ metabolizable energy (ME) and 140 g crude protein/kg,
and ewes consumed (on average) twice the estimated ME requirements for
optimal fetoplacental growth in this genotype. Viable pregnancies were
confirmed using transabdominal ultrasound in 33 of 44 ewes, giving an overall
pregnancy rate of 75%.
Ultrasound Assessment
At 79 6 0.1 days (0.5) gestation (term ¼ 145 days) ewes underwent
detailed ultrasound examination (while awake and upright) incorporating
baseline measurements of fetal abdominal circumference (AC) and renal
volume (RV), which we have previously shown are the strongest markers of
ovine fetal growth [27, 28]. Ultrasound scans were repeated at approximately
weekly intervals on four occasions between 101 6 0.1 and 133 6 0.3-days
gestation. All examinations were performed by a single operator accredited in
advanced obstetric ultrasound (DJC) blind to treatment allocation using a Logiq
400 CL machine (GE, Milwaukee, WI) and a 5.0 MHz curvilinear probe.
Gene Therapy Administration
At 886 0.7-days gestation ewes underwent a midline laparotomy. Anesthesia
was induced with 5 mg/kg i.v. propofol and maintained by inhaled isoflurane.
Ewes were randomized (by J.M.W. and on the basis of baseline ultrasound
measurements of AC and RV) to receive bilateral UtA injections of Ad.VEGF-
A
165
vector (n¼ 17) or saline (n¼ 16) as a control treatment. The main trunk of
each UtA was occluded digitally and injected distal to the occlusion site with 10
ml normal saline with or without 53 1011 particles first generation replication
deficient Ads (E1, E3-deleted, titre determined at optical density at 260 nm; Ark
Therapeutics Oy, Kuopio, Finland) containing the VEGF-A
165
gene, as previously
described [29]. The UtA occlusion was maintained for a total of 5 min
postinjection to minimize systemic vector spread.
Lambing and Neonatal Care
From 135 days gestation (the earliest point commensurate with live birth in
the overnourished adolescent paradigm) ewes were supervised 24 h/day and
allowed to spontaneously labor. A standardized proactive regimen of neonatal
care was used in anticipation of very high rates of neonatal mortality in this
FGR model (up to 62%) due to both prematurity and impaired passive
immunity and/or nutrient intake secondary to inadequate colostrum supply [16].
Maternal outcomes (labor complications, postpartum hemorrhage) and the
types and degree of immediate neonatal care provided were prespecified and
documented by caregivers (D.J.C., R.P.A., J.S.M.) blind to the treatment group.
After birth and any necessary resuscitation, lambs were dried and weighed. As
soon as possible (and always within 10 min), venous blood was sampled into a
heparinized tube and immediately centrifuged at 20003 g for 20 min at 48C to
facilitate plasma harvest. At the same time, heparinized whole venous blood
was analyzed immediately using an OSM 3 Hemoximeter (Radiometer Medical
A/S, Copenhagen, Denmark) to measure hemoglobin and hemoximetry, and the
hematocrit was determined in duplicate using a tube reader after centrifugation
for 3 min at 12 000 rpm (Micro Hematocrit MK-IV; Hawksley and Sons Ltd.,
Lancing, Sussex, U.K.). Next, measurements of umbilical girth and biparietal
head diameter were made using string and a ruler, and calipers, respectively.
After delivery, 10 IU i.v. oxytocin (Intervet UK, Ltd., Milton Keynes, U.K.)
was administered to each ewe in order to induce milk letdown. The udder was
stripped and the total volume of colostrum was determined before being fed
back to the lamb by bottle or feeding tube. A small sample of colostrum was
retained for quantification of immunoglobulin (Ig) G, energy, and nutrient
content (see below). It is recognized that lambs require at least 50 ml/kg birth
weight to acquire sufficient antibody protection [30]. Accordingly, when
maternal colostrum yield fell below this minimum requirement, the difference
in volume was provided to the lamb in the form of pooled donor colostrum of
known IgG and nutrient content. Finally, at 1 h of age, after allowing for
stabilization of physiological parameters, vital signs were recorded, including
respiratory rate, heart rate, and rectal temperature. Following delivery of the
placenta (comprising fetal cotyledons and membranes), its weight was
measured and cotyledons were dissected, counted, and weighed. All lambs
CARR ET AL.
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were weighed at 4-h intervals for the first 3 days and 8-h intervals between 4
and 7 days of life. Any lambs that failed to spontaneously suckle or gain weight
over an 8-h period were provided with supplementary colostrum, ewe milk, or
formula milk appropriate for stage and for as long as required, and the total
number and frequency of these supplementary feeds were recorded. All lambs
routinely received intramuscular vitamin E and selenium supplementation and
prophylactic antibiotics for a total of 5 days. To reduce the risk of infection,
each lamb’s navel was dipped in iodine at birth and at 12 h of age. In addition,
at 24 h of age, paired maternal and fetal venous blood samples were taken,
processed, and stored for quantification of plasma IgG levels.
Postnatal Investigations
Following the initially intensive period of neonatal care, serial measure-
ments of lamb body weight and umbilical girth were taken at weekly intervals
until ;12 wk of age in order to determine their absolute and fractional growth
rates. Fractional growth rates (% per day) were calculated by expressing the live
weight gain between birth and necropsy as a proportion of lamb birth weight
and dividing by the time interval between birth and necropsy. Venous blood
was sampled at weekly intervals for determination of serial plasma insulin and
IGF1 concentrations. At 8 days of age, an additional venous blood sample was
acquired to measure serum biochemistry (sodium, potassium, chloride, urea,
and creatinine) and liver function tests (alanine transaminase [ALT], aspartate
transferase [AST], gamma-glutamyl transferase [GGT], glutamate dehydroge-
nase [GLDH], alkaline phosphatase [ALP] and albumin). At 68 6 0.5 days of
age, all lambs underwent an i.v. glucose tolerance test, as previously described
[14]. Briefly, following a 3-h fast, lambs were blood sampled at20,10, 0,
þ5, þ10, þ15, þ20, þ25, þ30, þ45, þ60, þ90, and þ120 min relative to a
standardized i.v. glucose bolus (0.25 g/kg), and the resultant plasma was
analyzed for glucose and insulin. Fasting levels and AUC for insulin and
glucose were determined and additionally used to calculate a number of
established markers of insulin resistance, including the Homeostatic Model
Assessment (HOMA) index, which was calculated as the product of the fasting
glucose level (mass concentration in mg/dl) and the fasting insulin level,
divided by the appropriate constant (405). Thereafter, at 74 6 0.4 days
postnatal age, lambs underwent a noninvasive assessment of body composition
using DEXA under general anesthesia, which was induced and maintained
using isoflurane in a mixture of oxygen and nitrous oxide. Lambs were imaged
lying prone in a Norland XR-26 Mark II analyzer (Norland Corp., Fort
Atkinson, WI). Lambs were standing and eating within 15 min of general
anesthesia ceasing. Semiautomated analyses were repeated three times for
accuracy (coefficient of variation, ,5%).
Necropsy and Tissue Sampling
At 83 6 0.2 days postnatal age, one further blood sample was taken for
final measurements of insulin and IGF1 plus a single time point assessment of
plasma leptin. Thereafter, all lambs were humanely killed by an i.v. injection of
pentobarbital sodium (20 ml) and underwent postmortem examination. All
major internal organs were examined macroscopically and weighed. Samples of
hepatic tissue were snap frozen in isopentane chilled with liquid nitrogen and
stored at 808C pending DNA and RNA extraction.
Laboratory Analyses
Plasma glucose levels were determined in lamb blood samples using a dual
biochemistry analyzer (Model 2700; Yellow Springs Instruments, Yellow
Springs, OH), and variation between duplicates was ,5%. Plasma insulin,
IGF1, and leptin levels were determined using double antibody radioimmu-
noassays, as previously described [31–33]. The limits of sensitivity for the
insulin, IGF1, and leptin assays were 0.08, 0.04, and 0.05 ng/ml, respectively,
and intra- and interassay coefficients of variation ranged between 6.0% and
9.8%. Colostrum and plasma IgG content were determined in duplicate using
an ovine-specific ELISA, as described previously [27]. Colostrum samples
were diluted 1:100 000, while maternal and lamb plasma was diluted 1:30 000.
Intra- and interassay coefficients of variation were ,10%. Colostral fat,
protein, and lactose concentrations were determined in duplicate by previously
described methods [34, 35].
DNA Extraction and Bisulphite Sequencing
DNA methylation was quantified in the following eight genes of interest in
relation to postnatal growth and metabolism, as previously described [36]:
insulin (INS), IGF1, IGF2, H19, IGF receptor 1 (IGF1R) and 2 (IGF2R),
growth hormone receptor (GHR), and insulin receptor (INSR). Briefly, 25 mg of
hepatic tissue from each lamb was lysed and homogenized. DNA was
extracted, quality checked, and quantified, then 400 ng from each lamb was
treated overnight with sodium bisulphite, which selectively degrades
unmethylated C bases into uracil (that is subsequently converted to thiamine
[T]) and leaves methylated C bases intact. Percentage methylation was
quantified at 50 individual CpG sites across the 8 genes by pyrosequencing,
which measures the C:T ratios in the modified sample to determine the original
proportions of methylated versus unmethylated template DNA.
RNA Extraction and RT-PCR
An ovine-specific probe and primer set was custom designed using Primer
Express version 3.0 (Applied Biosystems, Foster City, CA) using a published
mRNA sequence for IGF1, hepatic mRNA expression of which has been shown
to differ by gender in this FGR model [36]. For each lamb, 30 mg hepatic tissue
was lysed and homogenized. RNA was extracted using the RNEasy Blood &
Tissue Kit (Qiagen, Hilden, Germany) and quantified and quality checked using
an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Next, 1
ng of each sample was reverse transcribed to cDNA using Superscript VILO
MasterMix (Invitrogen, Carlsbad, CA). The resultant cDNA was diluted with 480
ll RNAse-free water, combined with the required volumes of Taqman PCR
Mastermix, forward primer (50-TGTACTGTGCGCCTCTCAAG-30), reverse
primer (5 0-TGGGCATGTCGGTGTGG-3 0), and probe (5 0[6FAM]-
TCGGCCCGCTCAGTC-[TAMRA] 30), and run on a Taqman 7900HT fast
real-time PCR system (Applied Biosystems). The individual sample mRNA
expression was expressed relative to the geometric mean of the sample’s internal
beta-actin (ACTB) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
content, which was found to represent the most stable combination of
housekeeping genes for this particular species and tissue type using a geNorm
kit (Primerdesign Ltd., Southampton, U.K.). Ct values for all three genes were
first converted to mass (ng mRNA) using separate standard curves. Then, to
derive the relative gene expression, the quantity of IGF1 was divided by the
geometric mean of ACTB and GAPDH.
Statistical Analyses
An a priori power calculation was performed based on an anticipated 20%
increase in fetal size following Ad.VEGF-A
165
treatment. Assuming
interanimal variability of 607 g, it was estimated that 16 animals per group
would be required to detect a 20% increase in birth weight (719 g) with 90%
power. Results were analyzed using the Statistical Package for the Social
Sciences (SPSS) version 21.0 (SPSS Inc., Chicago, IL). After confirming
normality and equality of variance using Q-Q plots and Levene test,
respectively, comparisons between Ad.VEGF-A
165
and saline groups were
made using Student t-test. In anticipation of gender differences during
postnatal life, general linear model (GLM) was used to examine for putative
effects of prenatal Ad.VEGF-A
165
treatment, gender, and their potential
interaction. Wherever significant male versus female differences or
interactions were detected, results are presented as four groups in the tables.
GLM was further utilized to examine for differences between colostrum/milk
supplemented and nonsupplemented Ad.VEGF-A
165
and saline-treated lambs.
Categorical data were compared between groups using the chi-square test.
Correlations were assessed using Pearson product moment test. All data are
presented as mean 6 SEM unless otherwise stated. Formal statistical
significance was taken as P , 0.05 and a tendency towards a statistically
significant difference was taken as P ¼ 0.05–0.1.
RESULTS
There were no adverse maternal or fetal complications
during surgery or postoperatively, and all ewes remained in
good health throughout the study. There was one intrauterine
death (at 132 days gestation) of a saline-treated fetus that had
tracked extremely small on serial ultrasound examination; the
resultant stillborn lamb weighed 1496 g. All remaining
pregnancies continued uninterrupted and culminated in live
births at 141 6 0.2 days (range, 136 to 145 days gestation,
Table 1). Two lambs (,2.5 kg), both in the saline group,
required delivery by Caesarean section due to failure of
cervical dilatation; all other lambs were born vaginally. One
lamb in the Ad.VEGF-A
165
group was euthanized on welfare
grounds at 27 h of age after sustaining multiple rib fractures,
having been crushed by its mother. Complete datasets were
collected on 31 surviving lambs.
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Fetal Growth
Figure 1, A and B, shows serial ultrasound measurements of
the fetal AC and RV, respectively, from 766 0.1 until 1336 0.3
days gestation. Compared to equivalent presurgery baseline
values, measurements of both parameters increased to a greater
degree in Ad.VEGF-A
165
relative to saline groups, and were
larger at 108 6 0.1 days gestation (AC, 221 6 2.7 vs. 211 6 3.5
mm, P ¼ 0.02; RV, 5.14 6 0.193 vs. 4.37 6 0.165 cm3, P ,
0.01) and 116 6 0.1 days gestation (AC, 239 6 2.6 vs. 226 6
3.9 mm, P¼ 0.02; RV, 6.46 0.22 vs. 5.66 0.28 cm3, P¼ 0.04),
corresponding to 21 and 28 days postinjection, respectively. There
were no significant differences in AC between groups at 133 6
0.3 days gestation, when the measurements were more variable;
however, there remained a trend towards greater RV values in the
Ad.VEGF-A
165
versus the saline groups at this final time point
(8.6 6 0.42 vs. 7.5 6 0.38 cm3, P¼ 0.06).
Pregnancy Outcome
Lamb birth weight, gestational age at delivery, and placental
data are presented in Table 1 and Figure 2. Both lamb birth
weight and gestation length tended to be greater in Ad.VEGF-
A
165
versus saline groups (P¼0.08–0.09). To assess whether this
apparent shift in birth weight was solely attributable to the mean
increase in gestation of 2 days, individual lamb birth weights
were adjusted to term for this genotype (145 days) and to the
mean gestational age at delivery (142 days) using the following
formula, as previously described [7]: adjusted birth weight ¼
birth weight3 1.01305 per day of gestation. The statistical trend
towards a difference in lamb birth weight between the groups
remained following correction for gestation length using either
approach. Notably, there were no very small lambs (,2.5 kg)
born following Ad.VEGF-A
165
treatment (0 of 17), compared
with 4 of 16 (25%) after saline injection (P , 0.05). The gender
distribution was even within groups and for the study overall (17
males and 16 females in total). There were no significant gender
effects on any parameters during fetal life or at birth. The birth
weight-to-placental weight ratio tended to be increased in the
Ad.VEGF-A
165
group compared with the saline group (P ¼
0.08), indicating enhanced placental efficiency, and there was
also a trend toward higher plasma glucose concentrations shortly
after birth (P ¼ 0.09), suggestive of increased placental nutrient
transfer. Measurements of abdominal girth and biparietal
diameter also tended to be higher for Ad.VEGF-A
165
-treated
lambs (P ¼ 0.06–0.07). There were no significant group
differences in plasma IGF1 or insulin levels at birth; however,
plasma insulin demonstrated a moderate correlation with lamb
birth weight in the saline group (r2¼0.69, n¼15, P, 0.01), but
not in the Ad.VEGF-A
165
group (r2 , 0.01, n¼ 17, P¼ 0.98).
By contrast, plasma IGF1 levels were positively correlated with
birth weight and total placental weight, irrespective of treatment
group (r2¼ 0.47 and r2¼ 0.38, respectively; n¼ 38, P , 0.01
each). There were no significant differences in quantity or quality
of colostrum (in terms of individual nutrient or IgG concentra-
tion/content) between the two groups (Table 2). No differences in
the length of labor or maternal blood loss at delivery were
observed between groups (data not shown).
Neonatal Care
There were no statistically significant differences between the
Ad.VEGF-A
165
group and saline group in the level of neonatal
care needed to ensure survival, including the number of lambs
requiring the following interventions: use of a heating lamp (1
vs. 7); supplementary feeding beyond initial feed at birth (10 vs.
7); use of donor colostrum (4 vs. 5); oxygen (0 vs. 1); steroids (0
vs. 1); respiratory stimulants (0 vs. 1); or additional antibiotics (0
vs. 1). Among lambs requiring supplementary feeding, there
were no differences between the Ad.VEGF-A
165
group and
saline group in the number of additional feeds required (66 3.0
vs. 13 6 5.4, P¼ 0.27) or total duration of feeding (64 6 24.0
vs. 70 6 24.2 h, P¼ 0.86). Lambs requiring feeding for longer
than 48 h (n ¼ 7) were of lower birth weight relative to other
lambs in the study (2931 6 467.3 vs. 4114 6 173.9 g, P ,
0.01), indicating that small size at birth was a strong predictor of
the need for prolonged supplementary feeding. The final
supplementary feed was given at 7 days of age to the smallest
surviving lamb in the study, which was born to a saline-treated
ewe, and weighed only 1720 g at birth. Postnatal growth
trajectory was unaffected by supplementation; thus, there were
no differences in overall weight gain between birth and necropsy
in supplemented and nonsupplemented lambs within the
Ad.VEGF-A
165
group (28.5 6 1.40 vs. 31.2 6 1.06 kg, P ¼
0.36) or the saline group (32.2 6 0.90 vs. 34.4 6 1.14 kg, P¼
0.55). Irrespective of treatment group, by 24 h, there were no
TABLE 1. Pregnancy outcome data and selected physical, metabolic, and hematological parameters at the time at birth.
Parameter Saline (n ¼ 16) Ad.VEGF-A
165
(n ¼ 17) P value
Lamb birth weight, g (range) 3433 6 303.3 (1496–6050) 4114 6 230.4 (2620–5540) 0.08
Gestation length, days (range) 140 6 0.8 (132–144) 142 6 0.4 (138–145) 0.07
Total fetal placental weight, g (range) 298 6 20.2 (186–438) 289 6 19.2 (164–416) 0.78
Cotyledon weight (g) 78 6 8.7 76 6 6.34 0.85
Cotyledon number 81 6 4.8 89 6 3.4 0.20
Mean cotyledon weight (g) 0.86 6 0.066 0.96 6 0.100 0.37
Birth weight-to-placental weight ratio 13.1 6 0.64 14.5 6 0.42 0.07
Male-to-female sex ratio 8:8 9:8 0.87
Birth weight adjusted to 142 days (g) 3449 6 283.6 4083 6 226.1 0.09
Birth weight adjusted to 145 days (g) 3634 6 298.1 4300 6 238.1 0.09
Biparietal head diameter (mm) 63.6 6 1.72 67.4 6 1.17 0.07
Umbilical girth (mm) 341 6 15.3 376 6 9.6 0.06
Glucose (mg/dl) 38.0 6 4.13 51.4 6 6.02 0.09
Hemoglobin (g/dl) 13.5 6 0.38 13.3 6 0.43 0.73
Hematocrit (%) 45.0 6 1.25 44.1 6 1.61 0.68
Methemoglobin (g/dl) 1.83 6 0.056 1.84 6 0.043 0.86
Carboxyhemoglobin (g/dl) 3.56 6 0.106 3.49 6 0.113 0.63
Venous oxygen saturation (%) 48.9 6 3.40 47.4 6 2.71 0.73
Venous oxygen content (mmol/L) 8.81 6 2.700 8.4 6 0.639 0.66
Insulin (ng/ml) 0.46 6 0.067 0.44 6 0.047 0.79
IGF1 (ng/ml) 0.12 6 0.015 0.15 6 0.017 0.29
CARR ET AL.
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differences in plasma IgG levels between supplemented and
nonsupplemented lambs (24.3 6 3.13 vs. 21.3 6 12.25 mg/ml,
P¼0.45), indicating that the neonatal care regimen was effective
in conferring passive immunity to lambs with low colostrum
availability at birth. There were also no differences between the
Ad.VEGF-A
165
group and saline group in any vital signs at 1 h
of age, specifically, heart rate (246 6 6.2 vs. 232 6 13.3 beats
min1, P¼ 0.34), respiratory rate (72 6 2.7 vs. 71 6 3.1 beats
min1, P ¼ 0.96), and temperature (39.9 6 0.14 vs. 39.8 6
0.208C, P ¼ 0.76). At 8 days of age, there were no significant
abnormalities or differences between the Ad.VEGF-A
165
group
and the saline group in serum concentrations of sodium (149.2
6 0.46 vs. 149.2 6 0.34 mmol/L, P ¼ 0.98), potassium (6.0
6 0.13 vs. 6.2 6 0.12 mmol/L, P ¼ 0.34), chloride (105.6 6
0.50 vs. 106.1 6 0.42 mmol/L, P¼ 0.51), urea (7.9 6 0.56 vs.
7.4 6 0.66 mmol/L, P¼ 0.62), creatinine (50.3 6 1.08 vs. 50.9
6 1.29 lmol/L, P¼ 0.71), ALT (4.26.0.34 vs. 3.9 6 0.25 IU/
L, P ¼ 0.56), AST (53.3 6 3.34 vs. 51.6 6 1.10 IU/L, P ¼
0.64), GGT (306 6 30.2 vs. 289 6 34.9 IU/L, P ¼ 0.72),
GLDH (15.0 6 3.09 vs. 27.4 6 12.40 IU/L, P ¼ 0.35), ALP
(1011 6 86.1 vs. 1034 6 81.4 IU/L, P ¼ 0.85), or albumin
(27.7 6 0.25 vs. 27.6 6 0.45 g/L, P¼ 0.85).
Postnatal Growth Rates
Figure 3 shows serial measurements of lamb body weight
and umbilical girth, as well as plasma levels of insulin and
IGF1 from birth until necropsy at 83 6 0.2 days of age. There
was a trend toward increased body weight in the Ad.VEGF-
A
165
group relative to the saline group between 14 and 35 days
of age (P ¼ 0.07 each) and, subsequently, live weight was
significantly increased in the Ad.VEGF-A
165
group versus the
saline group from 42 to 82 days postnatal age (P¼ 0.02–0.04).
Consequently, absolute postnatal growth rate from birth until
necropsy was increased in the Ad.VEGF-A
165
group versus the
saline group (397 6 8.7 vs. 362 6 11.7 g/day, P ¼ 0.02). In
contrast, fractional growth rate did not differ (10.0 6 0.61 vs.
10.7 6 0.76%/day, P ¼ 0.48). There were no differences in
absolute or fractional growth rate between male and female
lambs at any stage (P . 0.1). Measurements of umbilical girth
FIG. 2. Lamb birth weight and gestation length. A) Dot plot illustrating
individual birth weights following spontaneous delivery at 141 6 0.2 days
gestation in singleton-bearing adolescent ewes overnourished during
pregnancy to generate prenatal growth restriction and receiving bilateral
UtA injections of Ad.VEGF-A
165
(closed circles, n ¼ 17) or saline (open
circles, n¼ 16) at 88 6 0.7-days gestation. B) Histogram showing number
of lambs delivering per day between 132 and 145 days gestation. The
single (saline-treated) lamb that delivered at 132 days gestation was
stillborn. The remaining 32 lambs were live born.
FIG. 1. Ultrasound assessment of fetal growth. Serial ultrasound measure-
ments of fetal AC (A) and renal volume (RV; B) at regular intervals between
76 6 0.1 and 133 6 0.3 days gestation in singleton-bearing adolescent
ewes overnourished to generate FGR that received bilateral UtA injections of
Ad.VEGF-A
165
(closed circles, n¼ 17) or saline (open circles, n¼ 16) at 88
6 0.7 days gestation (indicated by arrow). Symbols denote gestational time
points at which there were statistically significant differences or trends
between groups: P¼ 0.05–0.1; *P , 0.05; **P , 0.01.
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were greater in the Ad.VEGF-A
165
group compared with the
saline group at 56, 77, and 82 days (P¼ 0.02–0.03) and tended
to be greater at 7, 14, 42, 63, and 70 days postnatal age (P ¼
0.06–0.1). Plasma insulin concentrations increased approxi-
mately five-fold by the end of the first week of life, at which
point levels tended to be higher in the Ad.VEGF-A
165
group
compared with the saline group (2.99 6 0.30 vs. 2.30 6 0.26
ng/ml, P , 0.1). Insulin concentrations subsequently stabilized
over the next 11 wk and did not significantly differ by
treatment group or by lamb gender at any point. By contrast,
plasma IGF1 levels tended to be higher in male versus female
lambs at 7 days of age (P ¼ 0.06), and thereafter were
significantly greater at all time points, except one (Day 21),
from 14 days onwards. However, there were no statistically
TABLE 2. Colostrum nutrient and IgG content immediately after birth and IgG concentrations in paired maternal and lamb plasma samples at 24 h of
age.
Parameter Saline (n ¼ 16) Ad.VEGF-A
165
(n ¼ 17) P value
Colostrum yield (ml) 266 6 39.1 314 6 48.5 0.45
Colostrum butterfat concentration (g/100 g) 7.74 6 1.274 7.43 6 0.958 0.85
Total colostrum butterfat content (g) 23.0 6 4.42 23.0 6 3.74 1.00
Colostrum lactose concentration (g/100 g) 1.54 6 0.15 1.72 6 0.12 0.40
Total colostrum lactose content (g) 5.03 6 0.92 4.46 6 0.79 0.63
Colostrum crude protein concentration (g/100 g) 18.5 6 1.11 19.3 6 1.06 0.57
Total colostrum crude protein content (g) 46.4 6 6.75 56.6 6 8.17 0.35
Total colostrum energy content (kJ) 662 6 95.9 769 6 117.5 0.50
Colostrum IgG concentration (mg/ml) 50.8 6 3.48 56.8 6 5.74 0.40
Total colostrum IgG content (g) 12.7 6 1.84 15.9 6 2.20 0.28
Lamb plasma IgG (mg/ml) at 24 h 22.9 6 1.85 23.1 6 4.06 0.98
Maternal plasma IgG (mg/ml) at 24 h 12.3 6 0.79 12.0 6 1.81 0.88
FIG. 3. Postnatal growth rates (weight and girth) and serial measurements of plasma insulin and IGF1. Serial measurements of live weight (A), umbilical
girth (B), and plasma insulin (C) and IGF1 (D) levels measured by radioimmunoassay, at weekly intervals from birth until 83 6 0.2 days of age in 31
surviving prenatally growth-restricted male (M) and female (F) lambs whose overnourished adolescent mothers received bilateral UtA injections of
Ad.VEGF-A
165
(closed circles, n ¼ 16) or saline (open circles, n ¼ 15) at 88 6 0.7-days gestation. Symbols denote time points at which there were
statistically significant differences or trends toward differences between groups: P ¼ 0.05-0.1; *P , 0.05.
CARR ET AL.
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significant differences between the Ad.VEGF-A
165
group and
the saline group at any stage.
Glucose Tolerance Test
Figure 4 depicts the glucose and insulin responses to an i.v.
0.25mg/kg glucose bolus administered at 686 0.5 days postnatal
age. Fasting (baseline) levels were taken as the arithmetic mean of
three samples drawn at 20, 10, and 0 min relative to the
glucose load. There were no significant gender differences in
either metabolite at any stage of the test. Baseline glucose and
insulin levels did not differ between the Ad.VEGF-A165 group
and the saline group (84.0 6 2.01 vs. 84.2 6 1.27 mg/dl, P ¼
0.92, and 1.42 6 0.120 vs. 1.33 6 0.108 ng/ml, P ¼ 0.6,
respectively), and there were no differences in any of the
following markers of insulin resistance: fasting insulin-to-glucose
ratio (0.406 0.025 vs. 0.376 0.030, P¼0.45); fasting glucose-
to-insulin ratio (2.636 0.159 vs. 2.966 0.243, P¼0.27); insulin
AUC-to-glucose AUC ratio (1.086 0.137 vs. 1.046 0.190, P¼
0.86); glucose AUC-to-insulin AUC ratio (1.096 0.106 vs. 1.48
6 0.288, P¼ 0.21); and HOMA index (130 6 15.4 vs. 118 6
10.2, P¼ 0.51). Following the glucose bolus, insulin AUC was
greater in the Ad.VEGF-A165 group relative to the saline group
(112 6 10.5 vs. 82 6 12.1 ng/min/ml, P¼ 0.04). By contrast,
despite differences at various individual time points (see Fig. 4A),
glucose AUC did not differ between the Ad.VEGF-A165 group
and the saline group (26456 246.8 vs. 20516 241.3 mg/min/dl,
P¼ 0.43).
Lamb Body Composition
At assessment by DEXA, there were no differences between
the Ad.VEGF-A
165
group and the saline group in fat mass (3.02
6 0.339 vs. 2.43 6 0.350 kg, P¼ 0.22) or percentage body fat
(9.3 6 1.01 vs. 8.0 6 1.14%, P ¼ 0.38). By contrast, the
following parameters reflecting musculoskeletal mass tended to
be increased in the Ad.VEGF-A
165
group compared with the
saline group: BMD (0.51 6 0.010 vs. 0.48 6 0.010 g/cm, P¼
0.06); bone mineral content (BMC; 857 6 27.2 vs. 783 6 27.8
g, P¼ 0.07); and lean tissue mass (28.7 6 0.77 vs. 26.3 6 0.94
kg, P¼ 0.07).
Table 3 details brain and major visceral organ weights (from
necropsy at 12 wk of age) in absolute and relative (per kg
carcass weight) terms. In keeping with their significantly
greater body weight, Ad.VEGF-A
165
lambs demonstrated
significantly increased absolute liver weights, but these
differences were no longer significant when expressed per kg
carcass weight, indicating a proportionate shift in hepatic
growth. Absolute perirenal fat weight was significantly greater
in the Ad.VEGF-A
165
group versus the saline group and tended
to remain higher when expressed per kg carcass. Moreover,
there was a significant gender3 treatment interaction, with the
highest values being observed in the female lambs that had
received prenatal Ad.VEGF-A
165
treatment. Independent of
gender, absolute adrenal weight tended to be less, and relative
adrenal weight was significantly lower in the Ad.VEGF-A
165
group versus the saline group. In the latter group, relative
adrenal weight was inversely correlated with gestation length
(r2¼0.43, n¼15, P¼0.02). This relationship was not seen in
the Ad.VEGF-A
165
group (r2¼0.06, n¼ 16, P¼ 0.38). There
were no other significant differences in any lamb organ
weights, but the residual carcass (reflecting the muscle and
skeletal mass) was heavier in the Ad.VEGF-A165 group.
Measurements of plasma leptin and IGF1 prior to necropsy
did not differ between the Ad.VEGF-A
165
group and the saline
group, but, compared with females, male lambs demonstrated
higher IGF1 (0.40 6 0.03 vs. 0.31 6 0.02 ng/ml, P ¼ 0.04)
and lower leptin concentrations (2.51 6 0.36 vs. 4.48 6 0.56
ng/ml P¼ 0.02). There were no treatment or gender differences
in insulin levels at necropsy (P . 0.05).
DNA Methylation of Somatotropic Axis Genes
Table 4 details the mean DNA methylation across multiple
individual CpG sites in eight genes of interest in relation to
postnatal growth and metabolism. There were no significant
differences between the Ad.VEGF-A165 group and the saline
group in these averages, or at any individual CpG dinucleotides
(data not shown). DNA methylation of INS was greater in
males versus females (88.7 6 0.23 vs. 87.0 6 0.50%, P ,
0.01), while methylation of the IGF1 gene tended to be lower
(84.3 6 0.16 vs. 84.8 6 0.22%, P ¼ 0.05). Irrespective of
treatment group, INS methylation correlated negatively with
(fasting) baseline insulin levels measured prior to glucose
challenge (r2¼0.186, n ¼ 31, P ¼ 0.02).
FIG. 4. Intravenous glucose tolerance test. Serial measurements of
plasma glucose (A) and insulin (B) at regular intervals up to 120 min
following a standardized i.v. glucose infusion (0.25 mg/kg) administered at
68 6 0.5 days postnatal age in 31 surviving prenatally growth-restricted
lambs whose overnourished adolescent mothers received bilateral UtA
injections of Ad.VEGF-A
165
(closed circles, n¼16) or saline (open circles,
n ¼ 15) at 88 6 0.7 days gestation. Symbols denote time points with
statistically significant differences or trends toward a difference between
the groups: P¼ 0.05–0.1; *P , 0.05.
VEGF GENE THERAPY IN GROWTH-RESTRICTED FETAL SHEEP
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Table 5 details the mRNA expression data for IGF1,
expressed relative to the geometric mean of GAPDH and ACTB.
There was no significant effect of prenatal Ad.VEGF-A165 gene
therapy; however, irrespective of treatment group, IGF1 was
greater in males versus females (1.10 6 0.01 vs. 1.06 6 0.01, P
, 0.05). This difference is in the opposite direction to the DNA
methylation data (as expected) and in agreement with the higher
plasma IGF1 levels in male versus female lambs in serial blood
samples taken between 14 and 82 days postnatal age.
DISCUSSION
In the present study, which used a balanced design whereby
groups were equivalent in terms of key ultrasound parameters of
size prior to surgery, we observed a significant increase in
ultrasonographic fetal growth velocity (measured by a single
operator blinded to treatment group) in the growth-restricted
fetuses of overnourished adolescent ewes receiving bilateral
injections of Ad.VEGF-A
165
into the UtAs at midgestation
compared with injections of an inactive substance (saline). No
serious adverse effects were encountered following gene therapy
administration in the limited number of observations made. All
Ad.VEGF-A
165
-treated pregnancies continued until term and
followed an uncomplicated course. After spontaneous delivery
near to term, lamb birth weight and abdominal girth (which
directly reflects the ultrasonographic AC measurement) tended to
be higher in the Ad.VEGF-A
165
group compared with the saline
group, in agreement with the late-gestation ultrasound findings.
Furthermore, the mean increase in birth weight in the Ad.VEGF-
A
165
group versus the saline group was 681 g (;20%) in keeping
with the 18% increase in ultrasonographic measurements of fetal
size and anticipated size of effect used for the a priori power
calculation (719 g; 20%). Physical measurements at the time of
birth, including biparietal head diameter, also tended to be greater
in the Ad.VEGF-A
165
group versus the saline group, suggesting a
proportionate increase in brain and somatic growth.
Gestation length tended to be increased in the Ad.VEGF-A
165
group compared with the saline group. Importantly, the tendency
towards higher birth weight in the Ad.VEGF-A165 group was
not solely explained by this modest prolongation of pregnancy,
TABLE 3. Necropsy parameters at 83 days of age.
Parameter
F-saline
(n ¼ 8)
M-saline
(n ¼ 7)
F-Ad.VEGF A
165
(n ¼ 8)
M-Ad.VEGF A
165
(n ¼ 8)
P valuesa
Treatment Gender Interaction
Body weight (kg) 31.9 6 1.43 35.3 6 1.76 36.9 6 1.10 37.4 6 1.53 0.02 0.20 0.32
Carcass weight (kg) 19.3 6 1.04 20.5 6 1.05 25.7 6 0.91 25.4 6 1.00 0.04 0.87 0.33
Brain weight (g) 69.6 6 1.11 71.2 6 2.95 72.5 6 0.91 72.5 6 2.17 0.29 0.69 0.71
Relative brain weight (g/kg carcass
weight)
3.66 6 0.23 3.49 6 0.08 3.43 6 0.14 3.37 6 0.15 0.11 0.81 0.39
Liver weight (g) 560 6 24.4 630 6 24.7 651 6 20.2 659 6 22.9 0.02 0.10 0.19
Relative liver weight (g/kg carcass
weight)
29.2 6 1.22 30.9 6 0.77 29.2 6 0.79 30.8 6 1.61 0.97 0.15 0.97
Weight of adrenals (g) 1.78 6 0.050 1.84 6 0.051 1.61 6 0.069 1.76 6 0.085 0.08 0.14 0.57
Relative adrenal weight (g/kg carcass
weight)
0.094 6 0.006 0.091 6 0.005 0.072 6 0.002 0.083 6 0.005 ,0.01 0.37 0.13
Perirenal fat weight (g) 308 6 36.4 226 6 33.7 498 6 53.7 233 6 26.1 0.02 ,0.01 0.03
Relative perirenal fat weight (g/kg
carcass weight)
15.8 6 1.30 10.9 6 1.42 21.8 6 1.71 10.7 6 1.01 0.06 ,0.01 0.04
Weight of kidneys (g) 106 6 5.2 124 6 7.3 124 6 5.4 122 6 6.1 0.25 0.20 0.12
Relative kidney weight (g/kg carcass
weight)
5.53 6 0.27 6.06 6 0.17 5.54 6 0.12 5.67 6 0.33 0.43 0.17 0.39
Pancreas weight (g) 33.8 6 2.34 38.9 6 2.26 39.3 6 1.13 39.5 6 2.06 0.16 0.19 0.23
Relative pancreas weight (g/kg carcass
weight)
1.75 6 0.09 1.90 6 0.06 1.78 6 0.10 1.87 6 0.05 0.97 0.14 0.72
Spleen weight (g) 135 6 11.8 155 6 20.2 149 6 12.2 149 6 6.7 0.81 0.42 0.46
Relative spleen weight (g/kg carcass
weight)
7.06 6 0.74 7.48 6 0.72 6.56 6 0.35 6.68 6 0.26 0.24 0.63 0.79
Plasma IGF1 (ng/ml) 0.32 6 0.02 0.39 6 0.04 0.29 6 0.01 0.39 6 0.05 0.63 0.04 0.74
Plasma insulin (ng/ml) 1.66 6 0.34 1.79 6 0.20 1.31 6 0.09 1.69 6 0.17 0.34 0.29 0.59
Plasma leptin (ng/ml) 4.07 6 0.92 2.43 6 0.59 4.91 6 0.99 2.62 6 0.74 0.52 0.02 0.68
a P values below the threshold for formal significance (P , 0.05) are indicated in bold.
TABLE 4. Percentage DNA methylation of eight somatotropic axis genes in lamb hepatic tissue at 83 days postnatal age.
Genea F-saline (n ¼ 8) M-saline (n ¼ 7) F-Ad.VEGF-A
165
(n ¼ 8) M-Ad.VEGF-A
165
(n ¼ 8)
P valuesb
Treatment Gender Interaction
INS 87.3 6 0.84 88.9 6 0.26 86.8 6 0.65 88.5 6 0.36 0.53 ,0.01 0.87
IGF1 84.8 6 0.51 84.5 6 0.30 84.8 6 0.14 84.1 6 0.15 0.44 0.05 0.64
IGF2 22.0 6 1.05 21.2 6 0.67 21.5 6 0.65 20.7 6 0.56 0.41 0.37 0.84
H19 40.2 6 1.41 40.2 6 0.48 40.1 6 0.48 39.4 6 0.67 0.53 0.86 0.66
GHR 2.53 6 0.42 2.45 6 0.29 2.28 6 0.21 3.41 6 0.81 0.45 0.27 0.21
IGF1R 43.4 6 2.30 42.0 6 1.38 40.5 6 0.96 42.4 6 0.94 0.20 0.54 0.13
IGF2R 47.4 6 0.47 47.7 6 0.78 48.8 6 1.16 48.8 6 1.16 0.69 0.53 0.87
INSR 79.6 6 1.28 79.2 6 0.61 79.0 6 0.87 78.6 6 0.43 0.23 0.28 0.57
a IGF(R)¼ IGF (receptor); INS¼ insulin; INSR¼ insulin receptor; GHR¼ growth hormone receptor.
b P values below the threshold for formal significance (P , 0.05) are indicated in bold.
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as the significance levels for the birth weight differences did not
change substantially after mathematical correction for gestation
length (P ¼ 0.08 each). Although the absolute difference in
gestation length was only 2 days, this is on a background of 5
days prematurity for the genotype in this model of FGR,
represented by the saline group (mean gestational age at
delivery, 140 days), which is precisely known in view of timed
conception. The proportion of lambs delivering prior to 140 days
gestation appeared to be reduced in the Ad.VEGF-A
165
group
relative to the saline group (five versus one), suggesting a
targeted effect in the most severely affected pregnancies. This is
in agreement with our previous observation that Ad.VEGF-A
165
reduced the proportion of markedly FGR pregnancies, implying
selective benefits in compromised pregnancies and limited
effects on the 50% of fetuses that are growing normally despite
maternal overnutrition [6]. Regardless, as sheep tolerate
prematurity poorly, even small changes in gestation length can
have relatively large effects on morbidity and mortality rates
during lambing, and a 2-day difference would be considered
clinically significant from a veterinary perspective. If this were
to be directly extrapolated to human pregnancy, an extension of
;4 days may seem less relevant for healthy term pregnancies,
but, in cases of FGR near to the threshold of viability, this might
well confer some clinical benefit on neonatal outcome.
Interestingly, at necropsy there was a reduction in the
relative adrenal weight in the Ad.VEGF-A
165
group relative to
the saline group. Relative adrenal weight is increased in the
late-gestation fetuses of overnourished adolescent dams [9, 17],
and may reflect the accelerated maturation of the adrenal gland
that is known to occur in several animal models of FGR,
presumably in response to increasingly poor transplacental
nutrient supply to the fetus. Increased relative adrenal weights
have also been documented in ovine models of FGR induced
by carunclectomy [37], placental embolization [38], and single
umbilical artery ligation [39]. In the present study, there was a
negative correlation between the relative adrenal weight and
gestation length in the saline group, implying the greater the
relative size of the adrenal, the earlier the onset of labor.
Moreover, there appeared to be a dissociation of this
relationship following Ad.VEGF-A165 treatment, in keeping
with the slight increase in gestation length seen in this group.
These observations support the concept of a functional
relationship between premature activation of the fetal hypo-
thalamic-pituitary-adrenal axis and the initiation of labor in this
model. However, it is a limitation of the present study that we
were unable to assess fetal adrenal function immediately prior
to parturition, for example, by measuring fetal cortisol levels.
Lambs born following Ad.VEGF-A
165
treatment continued to
grow at a faster rate during the first 12 wk of life, and were
significantly larger than lambs born to saline-treated ewes from 6
wk onward. Increased postnatal growth was apparent when
expressed in absolute terms, but not as a fraction of birth weight,
implying that there had been no disassociation of the normal
inverse relationship between lamb birth weight and fractional
growth rate. Previously, when the postnatal growth trajectories
of small lambs born to overnourished mothers were compared
with those of normally grown offspring from control-intake
pregnancies, the absolute growth rates to weaning were not
significantly different (368 6 13.4 vs. 359 6 10.9 g/day, P .
0.05), indicative of the phenomenon known as ‘‘catch up’’
growth [11, 13]. In the present study, mean fractional growth
rates in the Ad.VEGF-A
165
group (10.0% per day) were similar
in magnitude to those observed in lambs born to (untreated)
overnourished dams (10.1% per day), suggesting that the
increased absolute postnatal growth rates after Ad.VEGF-A
165
treatment were not excessive when compared to baseline for this
cohort of offspring, but, rather, reflected the relative size
advantage of these lambs at birth, magnified with advancing
postnatal age. These lambs appeared to be thriving following
prenatal treatment, as they remained in good health and were
growing at an appropriate rate. The lack of any significant
differences between groups in DNA methylation of the various
somatotropic axis genes examined herein, or in expression of
IGF1 at the mRNA or protein level, further supports this
assumption. However, we cannot say for certain that these
differences were not due to an intrauterine programming effect
that remained undetected by the assays utilized.
Despite the lack of any impact of FGR on the epigenetic
status of a panel of eight genes or mRNA/protein expression of
IGF1, there was evidence of sexual dimorphism with respect to
the IGF1 and INS genes. IGF1 mRNA expression was higher
and DNA methylation tended to be lower in male versus female
lambs, which is in keeping with the higher circulating
concentrations of IGF1 in males from early postnatal life, and
has been reported previously in our sheep model of FGR [36]. A
more novel observation was the finding that INS DNA
methylation was lower in females versus males, and correlated
inversely with fasting plasma insulin (irrespective of gender).
This relationship was in the expected direction, as higher degrees
of methylation would hypothetically be associated with less
transcription of the precursor protein preproinsulin, although the
physiological sequence of events thereafter is complex and was
not examined in any further detail by the present study.
There were no sex differences in any other metabolic
parameters; however, lambs born following prenatal Ad.-
VEGF-A
165
gene therapy demonstrated a significant increase
in insulin secretion (AUC) during the i.v. glucose tolerance test
compared to lambs whose mothers were treated with saline.
Reassuringly, however, glucose disposition (AUC) did not differ
between the groups, suggesting normal responsiveness to
insulin. Furthermore, there were no significant differences in
any markers of insulin sensitivity, such as insulin-to-glucose or
glucose-to-insulin AUC ratios. This implies that enhanced
insulin secretion did not reflect worsening of insulin resistance,
but, rather, an increased capacity to secrete insulin in the absence
of major alterations in peripheral insulin action. There were also
no significant differences in fasting levels of glucose or insulin,
TABLE 5. Relative mRNA expression of IGF1 in lamb hepatic tissue at 83 days of age.
Genea F-saline (n ¼ 8) M-saline (n ¼ 7) F-Ad.VEGF-A
165
(n ¼ 8) M-Ad.VEGF-A
165
(n ¼ 8)
P valuesb
Treatment Gender Interaction
IGF1c 1.06 6 0.024 1.08 6 0.026 1.05 6 0.018 1.10 6 0.025 0.87 ,0.05 0.66
ACTB 20.7 6 0.43 21.2 6 0.68 22.3 6 0.71 20.2 6 0.60 0.37 0.85 0.17
GAPDH 20.7 6 0.66 22.6 6 0.92 22.9 6 0.80 22.0 6 0.74 0.76 0.20 0.22
a ACTB¼ beta-actin; GAPDH¼ glyceraldehyde-3-phosphate dehydrogenase; IGF(R)¼ IGF (receptor).
b P values below the threshold for formal significance (P , 0.05) are indicated in bold.
c Expressed relative to geometric mean of ACTB þ GAPDH.
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suggesting that Ad.VEGF-A
165
treatment did not impact basal
metabolic function in either a positive or negative way.
It was initially reassuring that, despite the increased growth
rates following Ad.VEGF-A
165
, there were no differences in fat
mass or percentage body fat between the the Ad.VEGF-A
165
and
the saline group when examined by DEXA at 11 wk postnatal
age, but, rather, a tendency towards increased BMD, BMC, and
lean tissue mass. However, at the point of necropsy at 12 wk
postnatal age, the relative weight of the perirenal fat depot (g/kg
lamb) tended to be increased in the Ad.VEGF-A
165
group
relative to the saline group with a significant gender3 treatment
interaction, such that the greatest degree of adiposity was
observed in Ad.VEGF-A
165
-treated female lambs. This observa-
tion indicates a possible intrauterine programming effect, and
may suggest that females are more sensitive to putatively
enhanced nutrient supply in utero than males, although there
were no gender differences in ultrasonographic fetal growth or
lamb birth weight in the present study. Of note, we were most
likely underpowered to detect sex differences in the present
study, and had no control over lamb gender, as recruitment of
ewes into the study occurred at midgestation. By contrast, many
purely postnatal studies begin at birth and feature stratification by
gender. Regardless, there was no evidence that female and/or
Ad.VEGF-A
165
-treated lambs had a worse metabolic profile than
male and/or saline-treated lambs. Ultimately, the perirenal fat is
only one of several major fat depots in the body, and assessment
of total body fat stores by DEXA did not suggest any differences
in the overall degree of adiposity between Ad.VEGF-A
165
and
saline-treated lambs. It is also noteworthy that residual carcass
weights at necropsy were greater following Ad.VEGF-A
165
treatment, indicating enhanced lean tissue accretion.
The present study complements and extends the findings of
our previous investigation [6], which had its endpoint in late
gestation, in several respects. First, it has closely replicated our
earlier finding of increased fetal growth velocity at 3 and 4 wk
following maternal UtA Ad.VEGF-A
165
treatment. The absolute
change in fetal AC measurements relative to baseline at these
two time points was remarkably similar to that demonstrated
previously (75.8 6 2.16 vs. 75.6 6 3.62 mm and 93.1 6 2.57
vs. 92.1 6 4.31 mm at 3 and 4 wk, respectively), which adds
both precision and robustness to the estimate of effect size.
Relative to the change in fetal AC for the saline-treated
pregnancies, this corresponds to an additional 18% increase in
fetal growth, which was mirrored by the differential in
birthweight of 681 g (19.8% greater than saline-treated FGR
pregnancies). Although this difference did not reach statistical
significance (P¼ 0.08), in retrospect, this is likely to reflect the
much greater birthweight variability encountered in this study
compared to previous studies (SD, 1212 vs. 607 g), meaning we
were relatively underpowered to detect any difference attribut-
able to Ad.VEGF-A
165
on this background. This was largely due
to the inclusion of one unusually large fetus in the saline-treated
group (born weighing 6050 g), which greatly impacted the
variability, but was not excluded as an outlier. Moreover, an
anticipated birthweight increase of 20% may, in retrospect, have
been slightly overambitious, given that the size of the effect of
Ad.VEGF-A
165
on fetal weight at 131 days gestation in our
previous study was a (nonsignificant) 242 g (5.8%) compared to
saline-treated pregnancies of overnourished dams, despite
significant effects on ultrasonographic fetal growth velocity
and the proportion of fetuses demonstrating marked FGR [6].
Unfortunately, however, we did not have these data available at
the time that we commenced the present study.
Regardless, a 20% improvement in fetal growth, as
demonstrated by ultrasound, is likely to be clinically significant
in human pregnancies affected by FGR due to uteroplacental
insufficiency, as relatively small increases in growth (and/or
time spent in utero), particularly at the threshold of viability, can
translate into relatively large improvements in the rates of overall
and intact survival [40]. Second, there was a tendency toward
increased placental efficiency following Ad.VEGF-A
165
treat-
ment, in agreement with our previous study, in which fetal-to-
placental weight ratios were greatest in the Ad.VEGF-A
165
-
treated pregnancies and there was upregulation of caruncular
mRNA expression of VEGF receptors 1 and 2. Collectively,
these observations might reflect increased placental vascularity
and/or nutrient transport capacity. The latter is implied by the
trend toward increased plasma glucose levels observed in the
Ad.VEGF-A
165
-treated lambs at birth, which suggests enhanced
transplacental transfer. Finally, the current investigation adds
further to the safety profile of maternal Ad.VEGF-A
165
therapy
to treat uteroplacental FGR, for which there is currently no
effective treatment. There were no adverse responses of either
the mother or the fetus to the injection or the occlusion
procedure, and all Ad.VEGF-A
165
-treated pregnancies continued
until term, with no antenatal or intrapartum complications. There
were no acute concerns during the perinatal period, and no
significant differences in the level of neonatal care required to
ensure lamb survival. Moreover, Ad.VEGF-A
165
did not impact
colostrum yield or composition, or the number or frequency of
supplementary feeds, suggesting that its effects are localized to
the pregnant uterus without any impact on mammary gland
function. Neonatal serum biochemistry and liver function were
unaltered, which is particularly reassuring, as adenoviral vectors
can induce liver inflammation [41]. Previous work has shown no
evidence of transfer to the fetus following administration via the
maternal UtAs in sheep [29]. To investigate safety further, we
are currently conducting full reproductive toxicology experi-
ments as part of a program of work aiming to translate prenatal
maternal Ad.VEGF gene therapy into the clinic (European
Union Framework Programme 7 project EVERREST [does
vascular endothelial growth factor gene therapy safely improve
outcome in severe early-onset fetal growth restriction?]).
This study has some clear limitations. First, the greater-than-
expected variability in birthweight is likely to have left us
underpowered to detect differences in our primary outcome,
despite clear and statistically significant differences in various
ultrasonographic markers of fetal growth, which are arguably
more sensitive at picking up subtle shifts in the prenatal growth
trajectory [27, 28]. Second, while the lack of any significant
differences in DNA methylation of key somatotropic axis genes
is reassuring, it does not completely exclude an intrauterine
programming effect of prenatal Ad.VEGF-A165 gene therapy,
particularly given the observation that female Ad.VEGF-treated
fetuses had increased perirenal fat. Although the pyrosequencing
technique (following bisulphite conversion) interrogate CpG
methylation at specific loci with very high resolution, ultimately,
relatively few sites can be examined in a given assay, which
limits the extent of the assessment, particularly compared to the
genome-wide methylation arrays that are currently available for
other species, including humans and rodents (but not the sheep).
Although we used a validated approach [36] to target sites of
presumed biological significance, it remains possible that
significant changes in DNA methylation in other genes may
have been overlooked. In addition, we only examined a single
tissue at a single time point. Although liver is an excellent
candidate for epigenetic analyses, given its central role in
metabolism and postnatal growth via the GH-IGF1 axis [42], it
should be borne in mind that methylation changes (or any lack
thereof) observed in one organ cannot automatically be
extrapolated to another [43]. Given the apparent effects of
Ad.VEGF-A165 on perirenal fat deposition in female fetuses,
CARR ET AL.
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analysis of adipose tissue would be the appropriate next step to
further evaluate for potential programming effects.
In summary, midgestation delivery of Ad.VEGF-A
165
gene
therapy in FGR pregnancies induced by overnourishing adoles-
cent sheep dams significantly increased fetal growth velocity at 3
and 4 wk posttreatment compared to a saline control. The
resultant lambs tended to be heavier at birth, and there were no
differences between groups in the level of neonatal care required
to ensure survival. Ad.VEGF-A
165
-treated lambs demonstrated
accelerated absolute postnatal growth rates (with evidence of
enhanced lean tissue accretion) and increased insulin secretion
following a glucose challenge (in the absence of any changes in
insulin sensitivity), which likely represent a greater anabolic drive
in the Ad.VEGF-A
165
-treated animals. There were no differences
in DNA methylation of the key genes of the somatotropic axis, or
in mRNA or protein expression of IGF1, suggesting that these
postnatal effects were a reflection of the lambs’ relative size
advantage at birth, rather than an intrauterine programming effect.
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